Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects

作者：Feng Zhang, Zhuqing Li, Yanxin Wang, Chao Li, Chengzhi Lu · 发表于：Cardiovascular Innovations and Applications · 年份：2025 · DOI：10.15212/cvia.2024.0063 · 被引用次数：4 · 研究领域：Mitochondrial Function and Pathology、Cardiovascular Function and Risk Factors、Adipose Tissue and Metabolism

Diabetic cardiomyopathy (DCM) is a specific type of cardiomyopathy that is independent of hypertension and coronary artery disease, and is closely associated with the high incidence and mortality of heart failure in people with diabetes. DCM causes microvascular disease, myocardial metabolic disorder, and myocardial fibrosis, thereby leading to left ventricular remodeling, diastolic and/or systolic dysfunction, and eventually progressing to congestive heart failure. Recent studies have highlighted the crucial roles of mitochondrial dysfunction in the pathogenesis of DCM, including aspects such as glucose-lipid metabolic disorder, oxidative stress damage, calcium regulation disorder, respiratory chain uncoupling, kinetic imbalance, and mitochondrial DNA damage. Increasing numbers of targets and drugs are being identified to ameliorate mitochondrial dysfunction and consequently slow DCM progression. This article reviews the newly identified targets and drugs in the past decade, to provide new insights for DCM prevention and treatment.